BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for BioArctic and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-09-03 17:35 |
Major Shareholding Notification
BioArctics grundare har för avsikt att sälja en mindre del av sitt aktieinnehav
|
Swedish | 182.9 KB | |
2025-09-03 17:35 |
Major Shareholding Notification
BioArctic’s founders intend to divest minor part of their shareholding
|
English | 179.0 KB | |
2025-09-03 01:30 |
Regulatory News Service
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as …
|
English | 211.3 KB | |
2025-09-03 01:30 |
Regulatory News Service
Stegvis ansökningsprocess påbörjad för marknadsgodkännande i USA av Leqembi® Iq…
|
Swedish | 253.3 KB | |
2025-09-01 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in BioArctic AB (publ) as of August 29, 2025
|
English | 196.1 KB | |
2025-09-01 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i BioArctic AB (publ) per den 29 augusti 2025
|
Swedish | 209.2 KB | |
2025-08-29 23:56 |
Regulatory News Service
Amerikanska läkemedelsverket godkänner subkutan underhållsbehandling med Leqemb…
|
Swedish | 251.3 KB | |
2025-08-29 23:55 |
Regulatory News Service
US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for m…
|
English | 212.0 KB | |
2025-08-28 08:00 |
Interim Report
|
Swedish | 1.8 MB | |
2025-08-28 08:00 |
Interim Report
|
English | 1.6 MB | |
2025-08-26 07:05 |
M&A Activity
BioArctic och Novartis ingår options-, samarbets- och licensavtal som nyttjar B…
|
Swedish | 201.1 KB | |
2025-08-26 07:05 |
M&A Activity
BioArctic and Novartis sign an option, collaboration and license agreement usin…
|
English | 206.8 KB | |
2025-07-31 12:00 |
Regulatory News Service
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
|
English | 196.5 KB | |
2025-07-31 12:00 |
Earnings Release
Försäljningen av Leqembi® uppgick till 23,1 miljarder yen under det andra kvart…
|
Swedish | 223.3 KB | |
2025-06-13 08:00 |
Regulatory News Service
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive…
|
English | 188.3 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |